[A22-04] Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V

Last updated 19.04.2022

Project no.:

Commission awarded on 18.01.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Immune system and infections


Adults with COVID-19 disease who do not require supplemental oxygen and are at increased risk of developing a severe course of COVID-19

Result of dossier assessment:
  • Vaccinated patients: added benefit not proven
  • Unvaccinated patients: indication of non-quantifiable added benefit

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form